Skip to main content

Liver organoids: an in vitro 3D model for liver cancer study


Primary liver cancer (PLC) is the second leading cause of cancer mortality worldwide, and its morbidity unceasingly increases these years. Hepatitis B virus (HBV) infection accounted for approximately 50% of hepatocellular carcinoma (HCC) cases globally in 2015. Due to the lack of an effective model to study HBV-associated liver carcinogenesis, research has made slow progress. Organoid, an in vitro 3D model which maintains self-organization, has recently emerged as a powerful tool to investigate human diseases. In this review, we first summarize the categories and development of liver organoids. Then, we mainly focus on the functions of culture medium components and applications of organoids for HBV infection and HBV-associated liver cancer studies. Finally, we provide insights into a potential patient-derived organoid model from those infected with HBV based on our study, as well as the limitations and future applications of organoids in liver cancer research.


Primary liver cancer (PLC) is the second leading cause of cancer mortality worldwide, and its morbidity has continuously increased in recent years [1]. PLC comprises hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA), and other tumors, such as hepatoblastoma and fibrolamellar carcinoma. HCC is the dominant type with nearly 800,000 new cases annually, accounting for 90% of PLC cases [2]. iCCA is the second most prevalent PLC, and its incidence continuously grows [2, 3]. Some studies have elucidated that adult hepatocytes and progenitor cells are the sources of HCCs and can transform into iCCAs, while adult cholangiocytes can only give rise to iCCAs [2]. However, more researches are needed to investigate the cell origin of HCC and iCCA [2, 4]. Both HCC and iCCA are heterogenous diseases among patients and even within cancer cells derived from the same individual. The importance of personalized medicine is increasingly prominent.

As in vitro models for cancer research, traditional two-dimensional (2D) cell line cultures and mouse models are frequently utilized for preclinical studies. Despite their unique contributions to the development of cancer science, they are also fraught with some challenges. For example, 2D cell lines lack the capability of mimicking the architectural features of tumors. Genetically engineered mouse models (GEMMs) and patient-derived xenografts (PDXs) are time-consuming and economically unaffordable for some researchers [1, 5]. Compared with traditional 2D models, three-dimensional (3D) systems are more adept at representing the situation in vivo (Table 1).

Table 1 Comparison for key features between 2D cell lines and 3D organoids

As a branch of 3D models in vitro, organoids play an increasingly pivotal role in cancer research. Although many definitions exist for organoid, this term is now defined as a “self-organizing structure that is generated from stem cells that mimics the in vivo architecture and multi-lineage differentiation of the original tissue” [6]. In the past decades, studies have reported the generation of organoids of several different organs, including the retina [7, 8], brain [9], kidney [10], lung [11], prostate [12], colon [13], pancreas [14, 15], liver [16], and some cancer organoids, such as brain tumors [17], pancreatic cancer [18], and PLC [19].

In this review, we summarize the categories and development of liver organoids, as well as liver organoid culture and applications in cancer research, mainly focusing on the functions of culture medium components and applications for hepatitis B virus (HBV) infection and HBV-associated liver cancer studies. In addition, we provide insights into a potential patient-derived organoid model from those infected with HBV based on our study, as well as the limitations and future applications of organoids in liver cancer research.

Categories and development of liver organoids

The origin of organoids can be traced back to the research of silicious sponges by Wilson in 1907 [20]. He found sponges when kept in confinement under proper conditions degenerate, giving rise to small masses of undifferentiated tissue which in their turn are able to grow and differentiate into perfect sponges. It suggests the characteristic of self-organization exists in organisms, which is the key characteristic of organoids and the basis of organoid generation.

Organoids were once described as an in vitro 3D cellular cluster that can recapitulate the functionality of the origin tissue and are capable of self-renewal and self-organization [21, 22]. A landmark work in the field of organoids comes from the team of Hans Clevers in 2009. They have proven that there is a group of cells isolated from mouse intestinal tissue expressing the leucine-rich repeat-containing G-protein-coupled receptor 5 (Lgr5), and they are what we call Lgr5+ adult stem cells now. Based on these cells, organoids can be generated under special conditions with the characteristics of self-renewal and self-organization, that mimic the intestinal crypt-villus architecture and cell composition [23]. On the basis of this pioneering work, liver organoids get access rapidly from Lgr5+ mouse liver stem cells, although liver Lgr5+ cells can only be observed after chemical treatment induces liver damage [16] (Fig. 1).

Fig. 1
figure 1

Features of liver organoids. As one kind of organoid models, liver organoids have the characteristic of long-term expansion and self-organization. In addition, liver organoids are of heterogeneity and with unique morphology features. Hep-Orgs are of pseudoglandular rosettes and Chol-Orgs are cryptomere

Liver organoids can be divided into two groups: healthy and cancer organoids (Fig. 2). The former are usually derived from stem cells and normal tissue cells, including hepatocytes, cholangiocytes, and even fibroblasts. Some studies have stated that primary hepatocytes and cholangiocytes [24] can be used to generate liver organoids in both mice and human [25, 26]. Some studies have demonstrated that transdifferentiation occurs, which means that fibroblasts can be converted into hepatocyte-like cells by activation of liver transcription factors [27,28,29,30]. Based on that technology, Sun et al. established liver organoids in ultra-low adherent plates [31]. As for stem cells, Lgr5+ liver stem cells and human induced pluripotent stem cells (iPSCs) have been used. Lgr5+ cells can be induced into bipotent progenitor organoids with the ability to differentiate into functional hepatocytes [16, 24]. Hepato-biliary organoids, a kind of complex organoids, can be generated by co-differentiation of hepatocytes and cholangiocytes from iPSCs [32, 33]. Based on the generation of organoids, carcinogenesis models could be established by chemical treatment and genetic engineering editing [34, 35].

Fig. 2
figure 2

Liver organoids can be derived from various cells of origin. A Generation of liver organoids from healthy liver tissues. Liver organoids can be formed from hepatocytes, cholangiocytes and Lgr5+ liver stem cells. The isolated cells can be placed in Matrigel as extracellular matrix and seeded into culture vessels to generate organoids. Signaling pathways which are typically modulated to enable organoid formation are listed. B Generation of liver organoids from iPSCs. Liver organoids can be generated from iPSCs, usually by a three-stage differentiation process. Firstly, iPSCs can be derived to endoderm cells by exposure to Act A and Wnt. Then, these endoderm cells progress to a hepatic fate following induction of HGF and FGF signaling. These hepatic progenitors are hepatoblast-like cells and can form hepatocyte-like cells finally. C Generation of liver organoids from fibroblasts. Fibroblasts can be induced into hiHeps by exposure to FOXA3, HNF1A and HNF4A to activate trans-differentiation. Then, liver organoids can be generated from these hiHeps. D Generation of liver cancer organoids from liver cancer tissues. Similarly, liver cancer organoids can be formed from cancer cells isolated from cancer tissues. After seeding the isolated cells into culture vessels containing appropriate matrix, cancer organoids can be generated in the certain culture medium. Act A activin A, BMP bone morphogenetic protein, EGF epidermal growth factor, FGF fibroblast growth factor, HGF hepatocyte growth factor, iPSCs induced pluripotent stem cells, TGFbi transforming growth factor beta inhibitor, TNFa tumour necrosis factor-alpha

When the establishment of cancer organoids achieves great success, the meaning of organoids expands. Unlike healthy organoids, cancer organoids mainly originate from cancer cells. It has been reported that primary cancer cells isolated from mouse models and patients can be induced into organoids under special conditions. Success has been achieved in the establishment of malignant organoid models from mouse primary liver tumors, after isolation and culture of PLC tissue [36].

Patient-derived organoids (PDOs), a particular kind of cancer organoids, is widely used for cancer research to mimic the situation of primary cancers, especially at the malignant stage. There are two main sources of PDOs, needle biopsies and human tumor specimens by surgery. The process of building PDOs is similar to that of organoids from the mouse PLC model, and the overall efficiency is 37.5% for tumor specimens by surgery and 26% for biopsy samples [19, 37]. Vlachogiannis et al. stated that no inverse correlation was observed between the PDO establishment rate and the presence of necrosis based on research of PDOs established from metastatic gastrointestinal cancers [38]. Besides, no correlation was found between PDO take-up rate and tumor percentage, suggesting that even in cases of a low tumor/stroma ratio, PDOs could also be established. This might aid in circumventing the shortage of next-generation sequencing (NGS) and is better suited for precision medicine, including drug screening and prediction of treatment responses (Fig. 3).

Fig. 3
figure 3

Applications of liver organoids. A Organoids derived from healthy liver tissues can be used as a model in basic research to investigate the cells of origin for liver cancer and the mechanism of carcinogenesis, especially in the HBV-associated liver cancers. B Organoids derived from liver cancer tissues can be expanded in vitro and cryopreserved enabling the establishment of biobanks. This is mainly used for drug screening in personalized medicine. Additionally, liver cancer organoids make it possible for the co-culture between cancer cells and other cells in microenvironment. Based on this technology, more basic research can be performed

Culture medium of liver organoids

Basal medium

Advanced DMEM/F12 is a common basal medium used for mammalian cell culture in low concentrations of fetal bovine serum, which includes glucose, nonessential amino acids, sodium pyruvate, etc. When it is used for the culture of liver organoids, plenty of additional agents need to be supplemented (Table 2).

Table 2 Summary of culture medium compositions for liver organoids

HEPES is a buffer commonly used in cell culture to maintain the osmotic pressure of the culture system. B27 is an optimized serum-free supplement usually used to support the growth of embryonic, post-natal, and adult hippocampal and other central nervous system neurons. For organoid culture, B27 may suppress cell differentiation. N2 is also a supplement for serum-free neurons with similar function to B27 [39].

Amino acids are the basic needs of cell culture. For organoid culture, three amino acids should be supplemented because of their short half-life: l-glutamine, N-acetyl-l-cysteine and nicotinamide. l-glutamine is one of the nonessential amino acids with unique metabolic functions. It is a precursor for the synthesis of other amino acids, proteins, nucleotides, and many other biologically important molecules. l-Glutamine also participates in cellular energy metabolism and intercellular adhesion [40,41,42]. While, its autodegradation in water limits the use of l-Glutamine in cell culture. GlutaMAX is the common substitution of l-glutamine, because of its stability in water. N-Acetyl-l-cysteine, a precursor of glutathione, is an effective antioxidant and free radical scavenger, and can activate the PI3K/Akt signaling pathway to regulate cell proliferation, differentiation and apoptosis [43]. Nicotinamide, a member of the B vitamin family, participates in cellular energy metabolism and plays an important role in the self-renewal of HCC stem cells [44]. Some studies have reported that nicotinamide could promote the expansion of organoids by inhibiting the activity of SIRT1 to suppress cell differentiation [45].


Two different Wnt signaling cascades have been identified, called non-canonical and canonical pathways, the latter involving the β-catenin protein. The canonical pathway is an evolutionarily conserved signaling mechanism that regulates fundamental physiological and pathological processes. The role of the Wnt/β-catenin cascade in regulating liver homeostasis, regeneration, and tumorigenesis has been extensively reviewed [46,47,48]. Self-renewal of the stem cells in organoids requires activation of the Wnt pathway. Wnt3a is a key ligand of the canonical Wnt/β-catenin pathway and supports strongly increased self-renewal of organ and embryonic stem cells and the serum-free establishment of human organoids from healthy and diseased livers [49]. Similarly, R-spondin-1, an activator of the Wnt pathway, is also used for organoid culture to maintain high Wnt/β-catenin signaling activity [50]. It has been reported that R-spondin-1 is dispensable for the growth of liver organoids and costly, thus being removed from the culture medium [51].

Bone morphogenetic protein (BMP) belongs to the transforming growth factor beta (TGF-β) superfamily. BMP signaling cascades play a key role during embryonic development and maintenance of adult tissue homeostasis, as well as regulate cell proliferation, differentiation, migration, organization, and apoptosis [52, 53]. In the process of organoid development, BMP plays an active role [54, 55]. Noggin, an inhibitor of BMP-4 and BMP-7, suppresses the activation of BMP signaling cascades. Adding BMPs or removing Noggin, stem cells are lost from the cultures through differentiation towards adult cells [19, 56].

To maintain the growth and proliferation of organoids, certain growth factors are added to the culture medium. Epidermal growth factor (EGF) plays an irreplaceable role in signal transduction pathways that are involved in regulating cellular proliferation, differentiation, and survival by binding to its receptor, EGFR [57]. Fibroblast growth factors (FGFs) are a family of cell signaling proteins produced by macrophages. They participate in a wide variety of processes, especially as crucial elements for normal development in mammalian cells. A characteristic of FGFs is that they can bind to heparin and to heparin sulfate. Thus, some are sequestered in the extracellular matrix of tissues that contain heparin sulfate proteoglycans and are released locally upon injury or tissue remodeling [58]. Hepatocyte growth factor (HGF), secreted by mesenchymal cells, targets not only primarily epithelial cells and endothelial cells, but also haemopoietic progenitor cells and T cells. Its ability to stimulate mitogenesis, cell motility, and matrix invasion gives it a central role in angiogenesis, tumorigenesis, and tissue regeneration [59]. EGF, FGF and HGF are necessary growth factors for hepatocytes. It has been proven that hepatocytes can enter diffusely into proliferation under the influence of EGF, HGF and TGFα rather than other growth factors [60]. HGF can be used to promote liver stem cell expansion and rescue liver dysfunction combined with R-spondin-1 [61].

Gastrin and Forskolin are also widely used in liver organoid culture. Gastrin is an important peptide hormone in gastrointestinal tract, mainly secreted by G cells. It has been reported that gastrin is a growth factor for colorectal, stomach, liver, and pancreatic cancer [62]. Gastrin is customarily added to prolong the survival time of intestinal and liver organoids. Forskolin, an adenylate cyclase activator, is used to support liver organoids expansion [63, 64].


A83-01 is a potent inhibitor of TGF-β type I receptor ALK5 kinase, ALK4 and ALK7. It reduces the level of ALK-5-induced transcription and blocks the ALK4-TD- and ALK7-TD-induced transcription. A83-01 can decrease cell motility, adhesion and invasion increased by TGF-β1, but does not change cell proliferation [65].

A83-01 inhibits mesenchymal cells and supports epithelial cell growth whereas Y-27632 facilitates the attachment of primary cells in vitro [66, 67]. Y-27632 is an ATP-competitive inhibitor of ROCK-I and ROCK-II. Y-27632 can inhibit the apoptosis of embryonic stem cells by inhibiting ROCK and promote the self-renewal and proliferation of stem cells. To avoid the growth of noncancerous cells, R-spondin-1, Noggin and Wnt3A are removed by supplementation of the classical medium for liver organoid culture with dexamethasone and Y-27632 [68].

The GSK3β inhibitor CHIR99021 plays a regulatory role in a variety of signaling pathways such as TGF-β, Nodal and MAPK. Its effect on the Wnt/β-catenin pathway is dose-dependent. Low-dose CHIR is unable to support the survival of organoids. Increasing CHIR up to a high dose, enhanced Wnt target gene expression to a level similar to that of R-spondin1 treatment. Combining LDN-193189, a BMP type I receptor inhibitor, with CHIR could replace the role of Noggin in organoids [50].

Liver organoids for carcinogenesis research

Liver organoids to investigate HBV replication and HBV-associated carcinogenesis

It is estimated that 5% of the world population, or approximately 400 million people, are currently chronically infected with HBV [69, 70]. Moreover, HBV infection is the most prominent risk factor for HCC development, accounting for approximately 50% of cases globally in 2015 [71]. HBV is a member of the hepadnaviridae family, with an approximately 3.2 kilobase (kb) pair of partially double-stranded circular DNA genome. And this genome is attached to the viral polymerase at the 5′ end of the (-) strand [72]. When HBV infects hepatocytes, the pre-S domain of HBsAg is attached to sodium taurocholate co-transporting polypeptide (NTCP). Then, the virus enters cells by membrane fusion and internalization [73, 74] (Fig. 4A). Upon infection of hepatocytes, relaxed circular DNA (RC DNA) is released and converted to the covalently closed circular (ccc) DNA form, although the underlying mechanism is unknown. The cccDNA, which forms a minichromosome with high stability, originates at the initiation of the viral life cycle [75]. This minichromosome serves as a template for the transcription of pregenomic HBV RNA and generates 4 different mRNA transcripts (3.5 kb, 2.4 kb, 2.1 kb and 0.7 kb) [76]. Based on these findings, plenty of HBV proteins are generated, followed by viral assembly in the endoplasmic reticulum. After nucleocapsid and HBV surface proteins are packaged, mature HBV is released into the extracellular matrix.

Fig. 4
figure 4

HBV life cycle and the unpublished data of suppression of HBV expression in the PDO model. A HBV life cycle. HBV enters hepatocytes by membrane fusion and internalization through NTCP, followed by uncoating, and nuclear transport of the RC DNA. The RC DNA is converted to cccDNA, which serves as a template for the transcription of pregenomic HBV RNA and generates 4 different mRNA transcripts: 3.5 kb preC RNA and pgRNA, 2.4 and 2.1 kb preS/S mRNAs, and 0.7 kb HBx mRNA. These RNAs are exported to the cytoplasm, and plenty of HBV proteins are generated. pgRNA is selectively packaged inside core particles, followed by several progresses to generate RC DNA. Following viral assembly in the endoplasmic reticulum, mature HBV is released into the extracellular matrix. B Time course of relative HBsAg levels in expansion medium in the PDO model generated from patients infected with HBV. Error bars represent the mean ± SEM. C Heatmap of NTCP mRNA levels relative to GAPDH of different supplements added into basic medium with HEPES, B27, N2, Glutamax, N-acetyl-l-cysteine, EGF, FGF10 and HGF

Currently, models of HBV research can be divided into three kinds: cellular models, animal models and organoid models. In general, cellular models are unsuitable for HBV-associated carcinogenesis research, although they easily maintain HBV replication and cost little. Animal models, especially primates, support HBV infection and immune responses but are so expensive and too difficult to maintain. Compared with the two models mentioned above, organoid models are amenable to genetic modification and cost moderately. Moreover, organoids support the full HBV life cycle and are suitable for research on HBV-associated carcinogenesis [77]. To date, two organoid models have been established that describe the potential of liver organoids to study HBV infection and replication in vitro; the pluripotent stem cell-derived model by Nie et al. [78] and the adult stem cell-derived model by Crignis et al. [79] Nie et al. established a functional liver organoid (LO) model from human induced pluripotent stem cells (hiPSCs). In a 3D culture system, hiPSC-derived endodermal, mesenchymal, and endothelial cells are co-cultured with a certain medium. Based on cell–cell interactions, self-organization appears and functional organoids are generated when the cells mentioned above differentiate. These functional hiPSC-LOs can support the full HBV life cycle and mimic HBV-associated hepatic dysfunction, truly recapitulating host-virus interactions. Additionally, Crignis et al. proved that a liver organoid model may support HBV replication in vitro. Liver organoids are generated from healthy donors. Then, these organoids were efficiently infected with both recombinant virus and HBV-infected patient serum. Excitingly, HBsAg, HBeAg, HBV core proteins, and even cccDNA can be detected in the culture supernatant of organoids. In addition, they also generate polyclonal liver organoids transducted by lentivirus. This model can efficiently produce HBV in a certain expansion medium.

HBV contributes to HCC development through direct and indirect mechanisms. Reported mechanisms of HBV infection leading to the development of hepatocellular carcinoma mainly include: genomic instability caused by partial integration of viral DNA into the host cell genome, insertional mutations of cancer-related genes, and promoting transformation of truncated HBx and preS/S proteins. In addition, genome damage, abnormal regulation of the cell cycle, apoptosis and other signaling pathways caused by HBV long-term massive replication and massive expression of HBx and other viral proteins, as well as liver damage and liver fibrosis caused by the imbalance of the liver immune microenvironment are also important for the occurrence and development of HBV-associated liver cancers [80]. HBV genome integration affects the abnormal expression of a series of cancer-related genes, such as proliferation, apoptosis, transcription, development and differentiation through cis-acting [81,82,83]. Moreover, viral genome integration into virus-host chimeric proteins promotes cell cycle progression and hepatocellular carcinogenesis [84].

Because of the ability of liver organoids to support the full HBV life cycle, it is possible to study the roles of these viral proteins during the natural course of infection. And it comes true that investigating the downstream target genes and carcinogenesis mechanisms in a primary hepatocyte system by the exogenous expression of HBx protein or other candidate viral/host proteins in hepatocytes, because organoids can be genetically modified. Interestingly, Crignis et al. generated HBV-infected PDOs from non-tumor cirrhotic tissue of explants from liver transplant patients. Transcriptomic analysis of those organoids indicates that an aberrant early cancer gene signature exists, which clustered with the HCC cohort on The Cancer Genome Atlas Liver Hepatocellular Carcinoma dataset and away from healthy liver tissue. This clarifies the potential that HBV-infected PDOs may provide evidence of some invaluable novel biomarkers for HBV-associated carcinogenesis and cancer development in patients infected with HBV [79].

Organoids used for HBV research are only healthy ones rather than cancers. We can successfully study HBV replication or HBV-associated carcinogenesis by infecting healthy organoids exogenously. In fact, it is still a great challenge to establish a patient-derived organoid model from those infected with HBV that can stably maintain HBV replication in vitro. This type of organoid model may not only maintain the biological characteristics of the original cancer but also show the infection and replication of HBV endogenously on a cancer background. In our trial, in expansion medium, the expression of HBV was suppressed continually in the PDO model generated from patients infected with HBV (Fig. 4B). Crignis et al. reported that differentiated organoids maintained in differentiation medium are more efficiently infected and produce higher viral titers than those in expansion medium [79]. This indicates that organoids in differentiation medium seem to support HBV replication and expression. Furthermore, whether HBV infection and expression are affected by culture medium composition is unknown. We have proven that the expression of NTCP is unstable and unrepeatable between different organoids by changing the culture medium composition (Fig. 4C). However, it has been reported that the presence of NTCP alone on the cell membrane may not automatically make cells more conducive to infection [85]. These results imply that viral internalization may require some highly probable but currently unknown host factors. The role these unknown factors play in the suppression of HBV expression in organoid culture is difficult to clarify (Fig. 5). We assume that the culture system for liver PDOs may not support HBV replication and expression. This means that some compositions block the signaling pathway necessary for the HBV life cycle or that some compositions are lacking support. The expression of HBV can be maintained for a long time, although primary human hepatocytes (PHHs) are infected with HBV in the medium with Forskolin [86]. However, Forskolin may repress the expression of NTCP to suppress HBV infection in PDO culture (Fig. 4C). Whether this contradiction is led by other supplements, such as SB431542, IWP2, DAPT, and LDN193189, in PHH culture remains unknown. It has been demonstrated that the MAPK signaling pathway is closely related to HBV replication and expression. P38 MAPK is activated by HBsAg, and HBsAg production is attenuated by inhibiting the pathway [87]. HBx activates the p38 MAPK pathway, which in turn facilitates HBx-mediated STAT3 phosphorylation [88], while STAT3 directly binds to HBV X/EnhI to promote HBV replication [89]. HoxA10 interacts with p38 MAPK and recruits SHP-1 to repress HBV replication, as well as HoxA10 binds to the EnhI/X promoter and competes with STAT3 to attenuate HBV transcription [90]. Under culture of liver PDOs, whether the MAPK signaling pathway is repressed remains unclear. The study for establishing the model of liver PDOs with endogenous HBV expression may be a new starting point for HBV infection. Based on this model, more research can be performed to clarify the role that HBV plays in liver oncobiology.

Fig. 5
figure 5

Unknown features of patient-derived organoids from HBV+ patients. In basic research of HBV, whether there are other receptors except NTCP is still unknown. The differentiation level of HBV host cells also may influence the entering process of HBV. The role that other cells and cytokines in microenvironment play in the HBV life cycle requires more research. And whether the current culture system of PDOs is suitable for HBV replication or not remains unclear. More research is required to clarified the influence of additives in culture medium on HBV replication and the activity of HBV-associated signaling pathway. Before the culture of organoids, patients usually get anti-HBV therapies. The influence of these therapies remains unknown. The correlation between HBV copy number in serum and in culture medium requires more studies to clarify

Liver organoids for research on carcinogenesis without hepatitis virus

Although several studies have reported the cell origin and extracellular matrix of liver cancer, carcinogenesis is still unclear. With the explorations of liver organoids, our understanding of liver carcinogenesis may witness more advancement. Naruse et al. established an organoid-based carcinogenesis model induced by in vitro chemical treatment [34]. In their study, the model established with mouse tissue-derived organoids and diethylnitrosamine (DEN)-treated organoids showed carcinogenic histopathological characteristics, which could be applied to investigate early molecular events to clarify the carcinogenesis driven by chemical factors.

Moreover, Sun et al. described the first documentation of human hepatocytes into iCCA cells [31]. Organoids with liver architecture and function were established using directly reprogrammed human hepatocytes. Then, they observed excessive contact between mitochondria and endoplasmic reticulum membranes with the introduction of c-MYC which might be an unrecognized oncogenic event in liver carcinogenesis [91]. By tracing the process of carcinogenesis induced by RAS in hepatocyte organoids, hepatocytes expressed several characteristics that are unique in iCCA cells. Similarly, some studies stated that mutations affecting BAP1 might be involved in the carcinogenesis of iCCA [35, 92].

To interrogate the mechanism of biliary carcinogenesis, another model was established using organoids from murine liver and gallbladder [93]. The organoids were transduced with lentiviral vectors to reconstitute genetic alterations common in biliary tract cancers, and then inoculated into immunodeficient mice. Their results showed that mutant Kras could drive the development of iCCA and this model might accelerate research on carcinogenesis.

Drug screening and personalized medicine

As HCC is a cancer rich in heterogeneity among patients, and even within cancer cells derived from the same individual, personalized treatment is of great importance to meet the tenets of precision medicine. Some studies have proven that tumor organoids derived from human PLC retain features from their tissue of origin [19, 37], indicating it holds promise to leverage organoids, especially PDOs, in personalized medicine.

By establishing PDOs, it was demonstrated that miRNA21 appeared to mediate the resistance of CCA cells to HSP90 inhibitors and that HSP90 inhibitors might be developed for the treatment of CCA [94]. Hedgehog signaling and receptor tyrosine kinase-induced reactivation of the MEK/ERK and AKT signaling pathways might be related to sorafenib resistance [95, 96]. These studies show a perspective for research on drug resistance and personalized medicine.

The potential of tumor organoids in drug screening for HCC was stated by Li et al. [97]. They established multiple cancer organoid lines from distinct regions of the tumor for each primary human liver cancer surgical specimen. Then, 129 drugs were used for the treatment of 27 lines. As a result, a subset of drugs appeared pan-effective, displaying at least moderate activity in the majority of these cancer organoid lines, although the majority of drugs were either ineffective, or effective only in selected lines.

Some efforts have been made in the clinical use of PDOs from metastatic colorectal and gastroesophageal cancer, suggesting that PDOs can recapitulate patient responses and be implemented in personalized medicine programs [38]. It is worth anticipating the widespread use of organoids from PLCs in personalized medicine.

Conclusions and futures

Although many studies have concentrated on the cell origin and carcinogenesis of liver cancer by means of organoids, cancer microenvironment cells, such as immune cells and vascular cells, have been insufficiently explored. Efforts have been made in the co-culture of human induced pluripotent cells with human adipose microvascular endothelial cells [98], rat hepatocytes with rat stellate cells [99], especially human pancreatic cancer organoids with stromal and immune cells [100], and tumor organoids with peripheral blood lymphocytes [101]. More research could be conducted on the microenvironment under hepatitis B infection and antitumor immunity using liver organoids.

Liver organoids are widely used for investigations of various liver diseases, including hepatitis, chronic liver diseases, metabolic diseases, and liver cancer. However, most studies focus on adult liver disorders rather than infant illness. In the future, more attention could be paid to the generation of fetal hepatocyte organoids and hepatoblastoma organoids, the most common cancer of fetal livers [91].

In addition, nearly all studies of liver cancer using organoids are about PLC. However, metastatic hepatic carcinoma and metastatic tumors of the liver are rarely studied. Skardal et al. inoculated liver organoids with colon carcinoma cells to create liver-tumor organoids for in vitro modeling of liver metastasis [102]. This 3D liver-tumor organoid was proven to be a better model of metastatic tumors than 2D cell cultures. Although this kind of model could not mimic the actual situation of metastatic tumors of the liver completely, it is worth further research.

In this review, we summarize the categories and development of liver organoids, especially focus on the functions of culture medium components and applications of organoids for HBV infection and HBV-associated liver cancer studies. Moreover, we provide insights into a potential patient-derived organoid model from those infected with HBV based on our study. In summary, although the size of organoids and the time of culture impede the applications of organoids in liver cancer research, there is still substantial potential for research on organoids in liver cancer. Developing a biobank of liver cancer and precision medicine also requires more trials.

Availability of data and materials

All data used in this study are public.



Covalently closed circular DNA




Epidermal growth factor


Fibroblast growth factor


Genetically engineered mouse model


Hepatitis B Virus


Hepatocellular carcinoma


Hepatocyte growth factor


Intrahepatic cholangiocarcinoma


Induced pluripotent stem cell


Leucine-rich repeat-containing G-protein-coupled receptor 5


Liver organoid


Next-generation sequencing


Sodium taurocholate co-transporting polypeptide


Patient-derived organoid


Patient-derived xenograft


Primary liver cancer


Relaxed circular DNA


Transforming growth factor beta


  1. van Tienderen GS, Groot Koerkamp B, IJzermans JN, van der Laan LJW, Verstegen MMA. Recreating tumour complexity in a dish: organoid models to study liver cancer cells and their extracellular environment. Cancers (Basel). 2019;11(11):1706.

    Article  CAS  Google Scholar 

  2. Sia D, Villanueva A, Friedman SL, Llovet JM. Liver cancer cell of origin, molecular class, and effects on patient prognosis. Gastroenterology. 2017;152(4):745–61.

    Article  CAS  PubMed  Google Scholar 

  3. Bridgewater J, Galle PR, Khan SA, Llovet JM, Park JW, Patel T, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60(6):1268–89.

    Article  PubMed  Google Scholar 

  4. Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557–88.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Prior N, Inacio P, Huch M. Liver organoids: from basic research to therapeutic applications. Gut. 2019;68(12):2228–37.

    Article  CAS  PubMed  Google Scholar 

  6. Dutta D, Heo I, Clevers H. Disease modeling in stem cell-derived 3D organoid systems. Trends Mol Med. 2017;23(5):393–410.

    Article  CAS  PubMed  Google Scholar 

  7. Eiraku M, Takata N, Ishibashi H, Kawada M, Sakakura E, Okuda S, et al. Self-organizing optic-cup morphogenesis in three-dimensional culture. Nature. 2011;472(7341):51–6.

    Article  CAS  PubMed  Google Scholar 

  8. Nakano T, Ando S, Takata N, Kawada M, Muguruma K, Sekiguchi K, et al. Self-formation of optic cups and storable stratified neural retina from human ESCs. Cell Stem Cell. 2012;10(6):771–85.

    Article  CAS  PubMed  Google Scholar 

  9. Lancaster MA, Renner M, Martin CA, Wenzel D, Bicknell LS, Hurles ME, et al. Cerebral organoids model human brain development and microcephaly. Nature. 2013;501(7467):373–9.

    Article  CAS  PubMed  Google Scholar 

  10. Takasato M, Er PX, Chiu HS, Maier B, Baillie GJ, Ferguson C, et al. Kidney organoids from human iPS cells contain multiple lineages and model human nephrogenesis. Nature. 2015;526(7574):564–8.

    Article  CAS  PubMed  Google Scholar 

  11. Lee JH, Bhang DH, Beede A, Huang TL, Stripp BR, Bloch KD, et al. Lung stem cell differentiation in mice directed by endothelial cells via a BMP4-NFATc1-thrombospondin-1 axis. Cell. 2014;156(3):440–55.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Chua CW, Shibata M, Lei M, Toivanen R, Barlow LJ, Bergren SK, et al. Single luminal epithelial progenitors can generate prostate organoids in culture. Nat Cell Biol. 2014;16(10):951–61, 1–4.

  13. Sato T, Stange DE, Ferrante M, Vries RG, Van Es JH, Van den Brink S, et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett’s epithelium. Gastroenterology. 2011;141(5):1762–72.

    Article  CAS  PubMed  Google Scholar 

  14. Huch M, Bonfanti P, Boj SF, Sato T, Loomans CJ, van de Wetering M, et al. Unlimited in vitro expansion of adult bi-potent pancreas progenitors through the Lgr5/R-spondin axis. EMBO J. 2013;32(20):2708–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Loomans CJM, Williams Giuliani N, Balak J, Ringnalda F, van Gurp L, Huch M, et al. Expansion of adult human pancreatic tissue yields organoids harboring progenitor cells with endocrine differentiation potential. Stem Cell Rep. 2018;10(3):712–24.

    Article  CAS  Google Scholar 

  16. Huch M, Dorrell C, Boj SF, van Es JH, Li VS, van de Wetering M, et al. In vitro expansion of single Lgr5+ liver stem cells induced by Wnt-driven regeneration. Nature. 2013;494(7436):247–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Bian S, Repic M, Guo Z, Kavirayani A, Burkard T, Bagley JA, et al. Genetically engineered cerebral organoids model brain tumor formation. Nat Methods. 2018;15(8):631–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Boj SF, Hwang CI, Baker LA, Chio II, Engle DD, Corbo V, et al. Organoid models of human and mouse ductal pancreatic cancer. Cell. 2015;160(1–2):324–38.

    Article  CAS  PubMed  Google Scholar 

  19. Broutier L, Mastrogiovanni G, Verstegen MM, Francies HE, Gavarro LM, Bradshaw CR, et al. Human primary liver cancer-derived organoid cultures for disease modeling and drug screening. Nat Med. 2017;23(12):1424–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Wilson HV. A new method by which sponges may be artificially reared. Science. 1907;25(649):912–5.

    Article  CAS  PubMed  Google Scholar 

  21. Lancaster MA, Knoblich JA. Organogenesis in a dish: modeling development and disease using organoid technologies. Science. 2014;345(6194):1247125.

    Article  PubMed  CAS  Google Scholar 

  22. Huch M, Koo BK. Modeling mouse and human development using organoid cultures. Development. 2015;142(18):3113–25.

    Article  CAS  PubMed  Google Scholar 

  23. Sato T, Vries RG, Snippert HJ, van de Wetering M, Barker N, Stange DE, et al. Single Lgr5 stem cells build crypt-villus structures in vitro without a mesenchymal niche. Nature. 2009;459(7244):262–5.

    Article  CAS  PubMed  Google Scholar 

  24. Huch M, Gehart H, van Boxtel R, Hamer K, Blokzijl F, Verstegen MM, et al. Long-term culture of genome-stable bipotent stem cells from adult human liver. Cell. 2015;160(1–2):299–312.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Peng WC, Logan CY, Fish M, Anbarchian T, Aguisanda F, Alvarez-Varela A, et al. Inflammatory cytokine TNFalpha promotes the long-term expansion of primary hepatocytes in 3D culture. Cell. 2018;175(6):1607-1619.e15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Hu H, Gehart H, Artegiani B, Löpez-Iglesias C, Dekkers F, Basak O, et al. Long-term expansion of functional mouse and human hepatocytes as 3D organoids. Cell. 2018;175(6):1591-1606.e19.

    Article  CAS  PubMed  Google Scholar 

  27. Huang P, He Z, Ji S, Sun H, Xiang D, Liu C, et al. Induction of functional hepatocyte-like cells from mouse fibroblasts by defined factors. Nature. 2011;475(7356):386–9.

    Article  CAS  PubMed  Google Scholar 

  28. Huang P, Zhang L, Gao Y, He Z, Yao D, Wu Z, et al. Direct reprogramming of human fibroblasts to functional and expandable hepatocytes. Cell Stem Cell. 2014;14(3):370–84.

    Article  CAS  PubMed  Google Scholar 

  29. Sekiya S, Suzuki A. Direct conversion of mouse fibroblasts to hepatocyte-like cells by defined factors. Nature. 2011;475(7356):390–3.

    Article  CAS  PubMed  Google Scholar 

  30. Du Y, Wang J, Jia J, Song N, Xiang C, Xu J, et al. Human hepatocytes with drug metabolic function induced from fibroblasts by lineage reprogramming. Cell Stem Cell. 2014;14(3):394–403.

    Article  CAS  PubMed  Google Scholar 

  31. Sun L, Wang Y, Cen J, Ma X, Cui L, Qiu Z, et al. Modelling liver cancer initiation with organoids derived from directly reprogrammed human hepatocytes. Nat Cell Biol. 2019;21(8):1015–26.

    Article  CAS  PubMed  Google Scholar 

  32. Guan Y, Xu D, Garfin PM, Ehmer U, Hurwitz M, Enns G, et al. Human hepatic organoids for the analysis of human genetic diseases. JCI Insight. 2017;2(17): e94954.

    Article  PubMed Central  Google Scholar 

  33. Wu F, Wu D, Ren Y, Huang Y, Feng B, Zhao N, et al. Generation of hepatobiliary organoids from human induced pluripotent stem cells. J Hepatol. 2019;70(6):1145–58.

    Article  PubMed  Google Scholar 

  34. Naruse M, Masui R, Ochiai M, Maru Y, Hippo Y, Imai T. An organoid-based carcinogenesis model induced by in vitro chemical treatment. Carcinogenesis. 2020;41(10):1444–53.

    Article  CAS  PubMed  Google Scholar 

  35. Artegiani B, van Voorthuijsen L, Lindeboom RGH, Seinstra D, Heo I, Tapia P, et al. Probing the tumor suppressor function of BAP1 in CRISPR-engineered human liver organoids. Cell Stem Cell. 2019;24(6):927-943.e6.

    Article  CAS  PubMed  Google Scholar 

  36. Cao W, Liu J, Wang L, Li M, Verstegen MMA, Yin Y, et al. Modeling liver cancer and therapy responsiveness using organoids derived from primary mouse liver tumors. Carcinogenesis. 2019;40(1):145–54.

    Article  CAS  PubMed  Google Scholar 

  37. Nuciforo S, Fofana I, Matter MS, Blumer T, Calabrese D, Boldanova T, et al. Organoid models of human liver cancers derived from tumor needle biopsies. Cell Rep. 2018;24(5):1363–76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Vlachogiannis G, Hedayat S, Vatsiou A, Jamin Y, Fernandez-Mateos J, Khan K, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science. 2018;359(6378):920–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Sünwoldt J, Bosche B, Meisel A, Mergenthaler P. Neuronal culture microenvironments determine preferences in bioenergetic pathway use. Front Mol Neurosci. 2017;10:305.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  40. Eagle H, Piez K. The population-dependent requirement by cultured mammalian cells for metabolites which they can synthesize. J Exp Med. 1962;116(1):29–43.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. Li J, Ghazwani M, Liu K, Huang Y, Chang N, Fan J, et al. Regulation of hepatic stellate cell proliferation and activation by glutamine metabolism. PLoS ONE. 2017;12(8): e0182679.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  42. Oppenheimer SB, Edidin M, Orr CW, Roseman S. An L-glutamine requirement for intercellular adhesion. Proc Natl Acad Sci USA. 1969;63(4):1395–402.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Hamid ZA, Tan HY, Chow PW, Harto KAW, Chan CY, Mohamed J. The role of N-acetylcysteine supplementation on the oxidative stress levels, genotoxicity and lineage commitment potential of ex vivo murine haematopoietic stem/progenitor cells. Sultan Qaboos Univ Med J. 2018;18(2):e130–6.

    Article  PubMed  PubMed Central  Google Scholar 

  44. Wedeken L, Luo A, Tremblay JR, Rawson J, Jin L, Gao D, et al. Adult murine pancreatic progenitors require epidermal growth factor and nicotinamide for self-renewal and differentiation in a serum- and conditioned medium-free culture. Stem Cells Dev. 2017;26(8):599–607.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Guo Q, Chen S, Rao X, Li Y, Pan M, Fu G, et al. Inhibition of SIRT1 promotes taste bud stem cell survival and mitigates radiation-induced oral mucositis in mice. Am J Transl Res. 2019;11(8):4789–99.

    CAS  PubMed  PubMed Central  Google Scholar 

  46. Pez F, Lopez A, Kim M, Wands JR, Caron de Fromentel C, Merle P. Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. J Hepatol. 2013;59(5):1107–17.

    Article  CAS  PubMed  Google Scholar 

  47. Perugorria MJ, Olaizola P, Labiano I, Esparza-Baquer A, Marzioni M, Marin JJG, et al. Wnt-β-catenin signalling in liver development, health and disease. Nat Rev Gastroenterol Hepatol. 2019;16(2):121–36.

    Article  CAS  PubMed  Google Scholar 

  48. Xu C, Xu Z, Zhang Y, Evert M, Calvisi DF, Chen X. β-Catenin signaling in hepatocellular carcinoma. J Clin Invest. 2022;132(4): e154515.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  49. Tuysuz N, van Bloois L, van den Brink S, Begthel H, Verstegen MM, Cruz LJ, et al. Lipid-mediated Wnt protein stabilization enables serum-free culture of human organ stem cells. Nat Commun. 2017;8:14578.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Li Y, Liu Y, Liu B, Wang J, Wei S, Qi Z, et al. A growth factor-free culture system underscores the coordination between Wnt and BMP signaling in Lgr5(+) intestinal stem cell maintenance. Cell Discov. 2018;4:49.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  51. Mun SJ, Ryu JS, Lee MO, Son YS, Oh SJ, Cho HS, et al. Generation of expandable human pluripotent stem cell-derived hepatocyte-like liver organoids. J Hepatol. 2019;71(5):970–85.

    Article  CAS  PubMed  Google Scholar 

  52. Magro-Lopez E, Muñoz-Fernández M. The role of BMP signaling in female reproductive system development and function. Int J Mol Sci. 2021;22(21):11927.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Hogan BL. Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes Dev. 1996;10(13):1580–94.

    Article  CAS  PubMed  Google Scholar 

  54. Zhang Y, Huang S, Zhong W, Chen W, Yao B, Wang X. 3D organoids derived from the small intestine: an emerging tool for drug transport research. Acta Pharm Sin B. 2021;11(7):1697–707.

    Article  CAS  PubMed  Google Scholar 

  55. Clevers H. Modeling development and disease with organoids. Cell. 2016;165(7):1586–97.

    Article  CAS  PubMed  Google Scholar 

  56. Kuijk EW, Rasmussen S, Blokzijl F, Huch M, Gehart H, Toonen P, et al. Generation and characterization of rat liver stem cell lines and their engraftment in a rat model of liver failure. Sci Rep. 2016;6:22154.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys. 2004;59(2 Suppl):21–6.

    Article  CAS  PubMed  Google Scholar 

  58. Burgess WH, Maciag T. The heparin-binding (fibroblast) growth factor family of proteins. Annu Rev Biochem. 1989;58:575–606.

    Article  CAS  PubMed  Google Scholar 

  59. Johnson M, Koukoulis G, Matsumoto K, Nakamura T, Iyer A. Hepatocyte growth factor induces proliferation and morphogenesis in nonparenchymal epithelial liver cells. Hepatology. 1993;17(6):1052–61.

    Article  CAS  PubMed  Google Scholar 

  60. Block GD, Locker J, Bowen WC, Petersen BE, Katyal S, Strom SC, et al. Population expansion, clonal growth, and specific differentiation patterns in primary cultures of hepatocytes induced by HGF/SF, EGF and TGF alpha in a chemically defined (HGM) medium. J Cell Biol. 1996;132(6):1133–49.

    Article  CAS  PubMed  Google Scholar 

  61. Lin Y, Fang ZP, Liu HJ, Wang LJ, Cheng Z, Tang N, et al. HGF/R-spondin1 rescues liver dysfunction through the induction of Lgr5(+) liver stem cells. Nat Commun. 2017;8(1):1175.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  62. Maddalo G, Spolverato Y, Rugge M, Farinati F. Gastrin: from pathophysiology to cancer prevention and treatment. Eur J Cancer Prev. 2014;23(4):258–63.

    Article  CAS  PubMed  Google Scholar 

  63. Wang X, Ni C, Jiang N, Wei J, Liang J, Zhao B, et al. Generation of liver bipotential organoids with a small-molecule cocktail. J Mol Cell Biol. 2020;12(8):618–29.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  64. Muilwijk D, de Poel E, van Mourik P, Suen SWF, Vonk AM, Brunsveld JE, et al. Forskolin-induced organoid swelling is associated with long-term CF disease progression. Eur Respir J. 2022.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Yamamura S, Matsumura N, Mandai M, Huang Z, Oura T, Baba T, et al. The activated transforming growth factor-beta signaling pathway in peritoneal metastases is a potential therapeutic target in ovarian cancer. Int J Cancer. 2012;130(1):20–8.

    Article  CAS  PubMed  Google Scholar 

  66. Qiu Z, Zou K, Zhuang L, Qin J, Li H, Li C, et al. Hepatocellular carcinoma cell lines retain the genomic and transcriptomic landscapes of primary human cancers. Sci Rep. 2016;6:27411.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  67. Qiu Z, Li H, Zhang Z, Zhu Z, He S, Wang X, et al. A pharmacogenomic landscape in human liver cancers. Cancer Cell. 2019;36(2):179-93.e11.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  68. Lau HCH, Kranenburg O, Xiao H, Yu J. Organoid models of gastrointestinal cancers in basic and translational research. Nat Rev Gastroenterol Hepatol. 2020;17(4):203–22.

    Article  PubMed  Google Scholar 

  69. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142(6):1264-73.e1.

    Article  PubMed  Google Scholar 

  70. Thomas E, Yoneda M, Schiff ER. Viral hepatitis: past and future of HBV and HDV. Cold Spring Harb Perspect Med. 2015;5(2): a021345.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  71. Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, et al. Hepatocellular carcinoma. Nat Rev Dis Prim. 2021;7(1):6.

    Article  PubMed  Google Scholar 

  72. Gerlich WH, Robinson WS. Hepatitis B virus contains protein attached to the 5′ terminus of its complete DNA strand. Cell. 1980;21(3):801–9.

    Article  CAS  PubMed  Google Scholar 

  73. Klingmüller U, Schaller H. Hepadnavirus infection requires interaction between the viral pre-S domain and a specific hepatocellular receptor. J Virol. 1993;67(12):7414–22.

    Article  PubMed  PubMed Central  Google Scholar 

  74. Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, et al. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012;1: e00049.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  75. Nassal M. HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B. Gut. 2015;64(12):1972–84.

    Article  CAS  PubMed  Google Scholar 

  76. Tong S, Revill P. Overview of hepatitis B viral replication and genetic variability. J Hepatol. 2016;64(1 Suppl):S4-s16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Rao S, Hossain T, Mahmoudi T. 3D human liver organoids: an in vitro platform to investigate HBV infection, replication and liver tumorigenesis. Cancer Lett. 2021;506:35–44.

    Article  CAS  PubMed  Google Scholar 

  78. Nie YZ, Zheng YW, Miyakawa K, Murata S, Zhang RR, Sekine K, et al. Recapitulation of hepatitis B virus–host interactions in liver organoids from human induced pluripotent stem cells. EBioMedicine. 2018;35:114–23.

    Article  PubMed  PubMed Central  Google Scholar 

  79. De Crignis E, Hossain T, Romal S, Carofiglio F, Moulos P, Khalid MM, et al. Application of human liver organoids as a patient-derived primary model for HBV infection and related hepatocellular carcinoma. Elife. 2021;10: e60747.

    Article  PubMed  PubMed Central  Google Scholar 

  80. Levrero M, Zucman-Rossi J. Mechanisms of HBV-induced hepatocellular carcinoma. J Hepatol. 2016;64(1 Suppl):S84-s101.

    Article  CAS  PubMed  Google Scholar 

  81. Li X, Zhang J, Yang Z, Kang J, Jiang S, Zhang T, et al. The function of targeted host genes determines the oncogenicity of HBV integration in hepatocellular carcinoma. J Hepatol. 2014;60(5):975–84.

    Article  PubMed  CAS  Google Scholar 

  82. Zhao LH, Liu X, Yan HX, Li WY, Zeng X, Yang Y, et al. Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma. Nat Commun. 2016;7:12992.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Sung WK, Zheng H, Li S, Chen R, Liu X, Li Y, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet. 2012;44(7):765–9.

    Article  CAS  PubMed  Google Scholar 

  84. Chiu YT, Wong JK, Choi SW, Sze KM, Ho DW, Chan LK, et al. Novel pre-mRNA splicing of intronically integrated HBV generates oncogenic chimera in hepatocellular carcinoma. J Hepatol. 2016;64(6):1256–64.

    Article  CAS  PubMed  Google Scholar 

  85. Iwamoto M, Saso W, Sugiyama R, Ishii K, Ohki M, Nagamori S, et al. Epidermal growth factor receptor is a host-entry cofactor triggering hepatitis B virus internalization. Proc Natl Acad Sci USA. 2019;116(17):8487–92.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  86. Zai W, Hu K, Ye J, Ding J, Huang C, Li Y, et al. Long-term hepatitis B virus infection induces cytopathic effects in primary human hepatocytes, and can be partially reversed by antiviral therapy. Microbiol Spectr. 2022;10(1): e0132821.

    Article  PubMed  Google Scholar 

  87. Jan RH, Lin YL, Chen CJ, Lin TY, Hsu YC, Chen LK, et al. Hepatitis B virus surface antigen can activate human monocyte-derived dendritic cells by nuclear factor kappa B and p38 mitogen-activated protein kinase mediated signaling. Microbiol Immunol. 2012;56(10):719–27.

    Article  CAS  PubMed  Google Scholar 

  88. Tarn C, Zou L, Hullinger RL, Andrisani OM. Hepatitis B virus X protein activates the p38 mitogen-activated protein kinase pathway in dedifferentiated hepatocytes. J Virol. 2002;76(19):9763–72.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  89. Waris G, Siddiqui A. Interaction between STAT-3 and HNF-3 leads to the activation of liver-specific hepatitis B virus enhancer 1 function. J Virol. 2002;76(6):2721–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Yang Q, Zhang Q, Zhang X, You L, Wang W, Liu W, et al. HoxA10 facilitates SHP-1-catalyzed dephosphorylation of p38 MAPK/STAT3 to repress hepatitis B virus replication by a feedback regulatory mechanism. J Virol. 2019;93(7): e01607-18.

    Article  PubMed  PubMed Central  Google Scholar 

  91. Sun L, Hui L. Progress in human liver organoids. J Mol Cell Biol. 2020;12(8):607–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  92. Jiao Y, Pawlik TM, Anders RA, Selaru FM, Streppel MM, Lucas DJ, et al. Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas. Nat Genet. 2013;45(12):1470–3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  93. Ochiai M, Yoshihara Y, Maru Y, Tetsuya M, Izumiya M, Imai T, et al. Kras-driven heterotopic tumor development from hepatobiliary organoids. Carcinogenesis. 2019;40(9):1142–52.

    CAS  Google Scholar 

  94. Lampis A, Carotenuto P, Vlachogiannis G, Cascione L, Hedayat S, Burke R, et al. MIR21 drives resistance to heat shock protein 90 inhibition in cholangiocarcinoma. Gastroenterology. 2018;154(4):1066-1079.e5.

    Article  CAS  PubMed  Google Scholar 

  95. Wang S, Wang Y, Xun X, Zhang C, Xiang X, Cheng Q, et al. Hedgehog signaling promotes sorafenib resistance in hepatocellular carcinoma patient-derived organoids. J Exp Clin Cancer Res. 2020;39(1):22.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  96. Leung CON, Tong M, Chung KPS, Zhou L, Che N, Tang KH, et al. Overriding adaptive resistance to sorafenib through combination therapy with Src homology 2 domain-containing phosphatase 2 blockade in hepatocellular carcinoma. Hepatology. 2019;72(1):155–68.

    Article  CAS  Google Scholar 

  97. Li L, Knutsdottir H, Hui K, Weiss MJ, He J, Philosophe B, et al. Human primary liver cancer organoids reveal intratumor and interpatient drug response heterogeneity. JCI Insight. 2019;4(2): e121490.

    Article  PubMed Central  Google Scholar 

  98. Pettinato G, Lehoux S, Ramanathan R, Salem MM, He LX, Muse O, et al. Generation of fully functional hepatocyte-like organoids from human induced pluripotent stem cells mixed with endothelial cells. Sci Rep. 2019;9(1):8920.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  99. Abu-Absi SF, Hansen LK, Hu WS. Three-dimensional co-culture of hepatocytes and stellate cells. Cytotechnology. 2004;45(3):125–40.

    Article  PubMed  PubMed Central  Google Scholar 

  100. Tsai S, McOlash L, Palen K, Johnson B, Duris C, Yang Q, et al. Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models. BMC Cancer. 2018;18(1):335.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  101. Dijkstra KK, Cattaneo CM, Weeber F, Chalabi M, van de Haar J, Fanchi LF, et al. Generation of tumor-reactive T cells by co-culture of peripheral blood lymphocytes and tumor organoids. Cell. 2018;174(6):1586-1598.e12.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  102. Skardal A, Devarasetty M, Rodman C, Atala A, Soker S. Liver-tumor hybrid organoids for modeling tumor growth and drug response in vitro. Ann Biomed Eng. 2015;43(10):2361–73.

    Article  PubMed  PubMed Central  Google Scholar 

  103. Broutier L, Andersson-Rolf A, Hindley CJ, Boj SF, Clevers H, Koo BK, et al. Culture and establishment of self-renewing human and mouse adult liver and pancreas 3D organoids and their genetic manipulation. Nat Protoc. 2016;11(9):1724–43.

    Article  CAS  PubMed  Google Scholar 

  104. Yimlamai D, Christodoulou C, Galli GG, Yanger K, Pepe-Mooney B, Gurung B, et al. Hippo pathway activity influences liver cell fate. Cell. 2014;157(6):1324–38.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references


Not applicable.


This work was supported by grants from the National Natural Science Foundation of China (82003093), and Chen Xiao-Ping Foundation for the Development of Science and Technology of Hubei Province (CXPJJH12000001-2020326).

Author information

Authors and Affiliations



RD wrote and finished the manuscript and figures. BZ and XZ corrected the manuscript and carried out a critical review and commentary. All authors read and approved the final manuscript.

Corresponding authors

Correspondence to Bixiang Zhang or Xuewu Zhang.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

All authors approved the final manuscript.

Competing interests

The authors declare that they have no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dong, R., Zhang, B. & Zhang, X. Liver organoids: an in vitro 3D model for liver cancer study. Cell Biosci 12, 152 (2022).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: